KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Non Operating Income: 2012-2024

Historic Other Non Operating Income for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to -$3.3 million.

  • Travere Therapeutics' Other Non Operating Income fell 6.35% to $487,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$71,000, marking a year-over-year increase of 94.79%. This contributed to the annual value of -$3.3 million for FY2024, which is 308.16% down from last year.
  • As of FY2024, Travere Therapeutics' Other Non Operating Income stood at -$3.3 million, which was down 308.16% from $1.6 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Other Non Operating Income ranged from a high of $1.6 million in FY2023 and a low of -$7.6 million during FY2022.
  • For the 3-year period, Travere Therapeutics' Other Non Operating Income averaged around -$3.1 million, with its median value being -$3.3 million (2024).
  • As far as peak fluctuations go, Travere Therapeutics' Other Non Operating Income spiked by 552.23% in 2020, and later tumbled by 3,390.04% in 2022.
  • Travere Therapeutics' Other Non Operating Income (Yearly) stood at $1.4 million in 2020, then slumped by 83.73% to $231,000 in 2021, then crashed by 3,390.04% to -$7.6 million in 2022, then soared by 120.97% to $1.6 million in 2023, then plummeted by 308.16% to -$3.3 million in 2024.